{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-085182","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.707240+00:00","generated_at":"2026-06-24T05:49:41.646520+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ReShape Lifesciences appoints Paul F. Hickey as CEO, effective Aug 15, 2022","bullets":["Paul F. Hickey appointed President and CEO, succeeds Bart Bandy who departed to pursue other opportunities.","CFO Thomas Stankovich serves as interim CEO until Hickey joins; Dan Gladney becomes Executive Chair.","Hickey receives $400K base salary, bonus up to 50% of salary, and stock option grant of 4% fully diluted shares.","Stankovich receives retention bonus of 100% target 2022 cash bonus if employed through Dec 31, 2022.","Hickey previously SVP Marketing at EnteroMedics (predecessor ReShape) and CEO at Altimate Medical."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-085182","json":"https://secwatch.observer/filing/0001104659-22-085182.json","markdown":"https://secwatch.observer/filing/0001104659-22-085182.md","text":"https://secwatch.observer/filing/0001104659-22-085182.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000110465922085182/0001104659-22-085182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000110465922085182/tm2222383d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:49:41.646520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52ed370e76","claim":"Bart Bandy resigned as Member of the Board of Directors at Vyome Holdings, Inc.","evidence_excerpt":"Mr. Bandy also resigned from the Board of Directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000110465922085182/0001104659-22-085182-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"5976ab4438","claim":"Paul F. Hickey was appointed as Member of the Board of Directors at Vyome Holdings, Inc.","evidence_excerpt":"On July 27, 2022, ReShape Lifesciences Inc. (the “Company”) announced that its Board of Directors has appointed Paul F. Hickey as President and Chief Executive Officer and as a member of the Board of Directors, effective August 15, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000110465922085182/0001104659-22-085182-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"6a3ea9533a","claim":"Bart Bandy departed as President and Chief Executive Officer at Vyome Holdings, Inc.","evidence_excerpt":"Mr. Hickey succeeds Bart Bandy, who has separated from the Company to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000110465922085182/0001104659-22-085182-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"863d69dcd8","claim":"Paul F. Hickey was appointed as President and Chief Executive Officer at Vyome Holdings, Inc.","evidence_excerpt":"On July 27, 2022, ReShape Lifesciences Inc. (the “Company”) announced that its Board of Directors has appointed Paul F. Hickey as President and Chief Executive Officer and as a member of the Board of Directors, effective August 15, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000110465922085182/0001104659-22-085182-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"a150a00b66","claim":"Thomas Stankovich was appointed as Interim President and Chief Executive Officer at Vyome Holdings, Inc.","evidence_excerpt":"Thomas Stankovich, Chief Financial Officer of the Company, will serve as Interim President and Chief Executive Officer until Mr. Hickey joins the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000110465922085182/0001104659-22-085182-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c37134699e","claim":"Dan W. Gladney was appointed as Executive Chair at Vyome Holdings, Inc.","evidence_excerpt":"Dan W. Gladney, current Chair of the Board of Directors, will assume a more active role as Executive Chair, supporting Mr. Hickey and the Company on strategic matters","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000110465922085182/0001104659-22-085182-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chair"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}